These results have suggested that the level of Y907 phosphorylation of PARP-1 may serve as a biomarker to predict PARPi resistance and that the combination of c-Met and PARPi may benefit patients with high c-Met expression tumours (290,327). Here, PARP1 is linked to neoplasm.